Cambridge, Mass.-headquartered Flagship Pioneering Inc. opened its Asia-Pacific (APAC) headquarters in Singapore on June 1, BioWorldlearned from APAC chair and strategic adviser André Andonian in a May 30 interview.
Cambridge, Mass.-headquartered Flagship Pioneering Inc. opened its Asia-Pacific (APAC) headquarters in Singapore on June 1, BioWorldlearned from APAC chair and strategic adviser André Andonian in a May 30 interview.
Prologue Medicines Inc. has launched to develop therapeutics created from the viral proteome, which are proteins produced across all viruses. It’s a newer twist on harnessing the power of the proteins that regulate biology. The company was founded on the premise of peering beyond the human proteome to see if there were viral proteins that could become therapeutics, Theonie Anastassiadis, Prologue’s founding president, told BioWorld.
In a research collaboration that could bring in up to $600 million, Metaphore Biotechnologies Inc. has become the third Flagship Pioneering company this year to cut a development deal with mighty obesity space player Novo Nordisk A/S.
Prologue Medicines Inc. has launched to develop therapeutics created from the viral proteome, which are proteins produced across all viruses. It’s a newer twist on harnessing the power of the proteins that regulate biology.
A week after Bristol Myers Squibb Co. disclosed a significant restructuring plan to focus on long-term growth drivers, the big pharma partnered with Repertoire Immune Medicines Inc. in an early stage, multiyear collaboration to develop T-cell targeted medicines for up to three autoimmune diseases, paying $65 million up front, with a potential $1.8 billion in development, regulatory and commercial milestones, along with tiered royalties.
Major contract research development and manufacturing organizations (CDMO) out of Asia are announcing plans to ramp up production and antibody-drug conjugate (ADC) capabilities worldwide.
Major contract research development and manufacturing organizations (CDMO) out of Asia are announcing plans to ramp up production and antibody-drug conjugate (ADC) capabilities worldwide.
A deal crafted in May 2022 between Novo Nordisk A/S and Flagship Pioneering has culminated into two separate research collaborations that are worth up to $532 million each in up-front and milestone payments for Omega Therapeutics Inc. and Cellarity Inc.
Launching a company based on knowledge that “the fundamental principle that most people hold to be true is off by a trillion” is a rare opportunity, said Jake Rubens, co-founder and president of Quotient Therapeutics Inc., a company that emerged from stealth this week, backed by two years of platform development and a $50 million investment from Flagship Pioneering.
